ERBB2 and breast carcinoma: We have shown that the levels of CA 15-3, CA 27.29, and MCA in saliva significantly decreased among patients with the molecular biological subtype HER2(+) of breast cancer compared to HER2(−), the control group, and fibroadenomas.